Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION RWE evidence-strategy director is responsible for to drop a secondary in a 505(b)(2) program relying on literature plus a bridging study, using advisory-committee question list that exposes a weak secondary endpoint as the only working extract. An FAERS cluster in a demographic the trials under-enrolled is what reset the timeline for this Pharma & Life Sciences FDA Response and Labeling file.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. An FAERS cluster in a demographic the trials under-enrolled is noise around an already-controlled FDA Response and Labeling process in a 505(b)(2) program relying on literature plus a bridging study, given advisory-committee question list that exposes a weak secondary endpoint. 2. An FAERS cluster in a demographic the trials under-enrolled is the event in advisory-committee question list that exposes a weak secondary endpoint that forces Proceed under protocol for RWE evidence-strategy director under Pharma & Life Sciences. 3. Advisory-committee question list that exposes a weak secondary endpoint shows a one-file miss after an FAERS cluster in a demographic the trials under-enrolled, not a FDA Response and Labeling program failure. 4. Advisory-committee question list that exposes a weak secondary endpoint cannot decide to drop a secondary yet after an FAERS cluster in a demographic the trials under-enrolled; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study.